Clinical Trials Study
Copyright ©The Author(s) 2025.
World J Gastrointest Oncol. Apr 15, 2025; 17(4): 103131
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103131
Table 1 Clinicopathological characteristics of patients in the two groups, n (%)
Variables
Total (n = 115)
Control group (n = 56)
RH-endostatin group (n = 59)
χ2
P value
Sex0.0450.832
    Male73 (63.5)35 (62.5)38 (64.4)
    Female42 (36.5)21 (37.5)21 (35.6)
Age (59.4 ± 10.2 years)0.4750.491
    ≤ 6064 (55.7)33 (58.9)31 (52.5)
    > 6051 (44.3)23 (41.1)28 (47.5)
Location of tumor0.0360.982
    Lower 1/3 37 (32.2)18 (32.2)19 (32.2)
    Middle 1/3 32 (27.8)16 (28.5)16 (27.1)
    Upper 1/3 46 (40.0)22 (39.3)24 (40.7)
Degree of differentiation0.1410.707
    Well/moderate41 (35.7)19 (34.0)22 (37.3)
    Poor74 (64.3)37 (66.0)37 (62.7)
Amount of ascites1.1730.556
    Small17 (14.8)7 (12.5)10 (16.9)
    Moderate34 (29.6)15 (26.8)19 (32.2)
    Massive64 (55.6)34 (60.7)30 (50.8)
Peritoneal metastases1.7940.180
    Oligo21 (18.3)13 (23.2)8 (13.6)
    Multiple 94 (81.7)43 (76.8)51 (86.4)